Model-based subgroup analyses indicated minimal heterogeneity in the STZ-induced AD subgroup (I2 = 33%), moderate heterogeneity in the Aβ1–42-induced AD subgroup (I2 = 63%), and considerable heterogeneity in the transgenic AD (APP/PS1) subgroup (I2 = 92%). This evidence concerns the gene APP and Alzheimer disease.